Postpartum Hemorrhage Clinical Trial
Official title:
A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage
Oxytocin is normally given either rapidly into the vein (bolus) or put into an intravenous bag and administered more slowly, after delivery of the baby by cesarean section. Both of these methods are commonly used. To date there has been little research to demonstrate that one method of giving oxytocin is better than another in women who are more likely to bleed after delivery. The purpose of the study is to see whether a small bolus of oxytocin makes the uterus contract better to reduce bleeding and decreases the need to give additional oxytocin or more powerful drugs in women who are at risk for bleeding after delivery of their baby by cesarean section.
Oxytocin is normally given either rapidly into the vein (bolus) or put into an intravenous
bag and administered more slowly, after delivery of the baby by cesarean section. Both of
these methods are commonly used. To date there has been little research to demonstrate that
one method of giving oxytocin is better than another in women who are more likely to bleed
after delivery. The purpose of the study is to see whether a small bolus of oxytocin makes
the uterus contract better to reduce bleeding and decreases the need to give additional
oxytocin or more powerful drugs in women who are at risk for bleeding after delivery of
their baby by cesarean section.
Women who participate will be randomized (like a toss of a coin) to one of two groups.
Neither the woman nor the anesthesiologist nor the obstetrician will know which group they
are in.
In one group, the women will receive a small injection of saline (salt water) directly into
the vein via their intravenous (bolus) after their baby is born. In the other group, the
women will receive a small injection of oxytocin directly into the vein via their
intravenous (bolus) after their baby is born.
Both groups will have the standard amount of oxytocin given slowly (over a 30 minute period)
into the intravenous in their arm (infusion). The amount of oxytocin that is put into the
intravenous bag is a normal amount that would be given during cesarean section in any woman
not involved in the study and it will be started after the initial injection has been given.
The only difference between the two groups is that one group will have an extra dose of
oxytocin given directly into the vein via the intravenous while the other will have a saline
solution given directly into the vein via the intravenous.
Information that will be obtained during the study will include any decrease in blood
pressure or increase in heart rate at the time the saline or oxytocin is given directly into
the vein. The obstetrician will be asked to indicate how well the uterus is contracting and
they can ask the anesthesiologist to give more oxytocin or a more powerful drug if, in their
opinion, the uterus is not contracting well. This is the normal way that this is done.
If the woman should feel dizzy (possibly secondary to low blood pressure) their
anesthesiologist will treat them the same way as they would if this happened to any woman
who is not part of the study. In other words, the anesthesiologist and obstetrician will
treat the woman the way they normally would whether the woman was part of the study or not.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Completed |
NCT03344302 -
Oxytocin Administration During Cesarean Section
|
Phase 4 | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 | |
Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A |